Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial
Epistaxis is a common debilitating manifestation in hereditary hemorrhagic telangiectasia (HHT), due to mucocutaneous telangiectases. The epistaxis can be difficult to control despite available treatments. Dysregulated angiogenesis has been shown to be associated with telangiectases formation. Topic...
Main Authors: | Meir Mei-Zahav, Yulia Gendler, Elchanan Bruckheimer, Dario Prais, Einat Birk, Muhamad Watad, Neta Goldschmidt, Ethan Soudry |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/9/10/3130 |
Similar Items
-
Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report
by: Meir Mei-Zahav, et al.
Published: (2017-10-01) -
Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT)
by: John M. Lee, et al.
Published: (2019-10-01) -
Surgery or No Surgery? Exploring the Dilemma of Epistaxis Management in Patients with HHT
by: Giulio Cesare Passali, et al.
Published: (2024-03-01) -
Radiofrequency for Treatment of Refractory Epistaxis in Hereditary Hemorrhagic Telangiectasia
by: Mariana Donato, et al.
Published: (2018-01-01) -
Telangiectasia hemorrágica hereditaria: Presentación de un caso clínico y actualización bibliográfica Hereditary hemorrhagic telangiectasia: Clinical case report and literature update
by: C Comerio, et al.
Published: (2009-09-01)